Deals in Depth: April 2010
Executive SummaryApril's leaders included a $165mm deal that gave Allergan rights to Serenity's late-stage Ser120 for nocturia. Medtronic offered $313mm to buy cardiac device company ATS Medical. Of the nearly $1bn in IPO money, 85% came from one company - Shenzhen Hepalink Pharma. Follow-on dollars on the device side were strong, with two companies bringing over $70mm, while both biopharma and device companies together raised $568mm in private financings.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.